Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Evaluating next-generation immunotherapies in earlier lines of treatment in multiple myeloma

Maria-Victoria Mateos • 25 Aug 2022
IMS 2022
Multiple Myeloma Antibodies CAR-T

Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, shares her excitement for clinical trials evaluating next-generation immunotherapies including CAR-T therapies, bispecific antibodies, and antibody-drug conjugates (ADCs) in earlier lines of treatment in patients with multiple myeloma. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Maria-Victoria Mateos

2:44
Dual-targeting bispecific antibody alnuctamab in R/R multiple myeloma
Maria-Victoria Mateos • 9 Dec 2023
2:26
Preliminary results of GEM2017FIT: comparing induction therapies in fit elderly patients with MM
Maria-Victoria Mateos • 9 Dec 2023
4:21
CAR-T in multiple myeloma: progress in the space and what can be done to improve patient outcomes
Maria-Victoria Mateos • 17 Feb 2024
Latest advances in T-cell engaging therapies for multiple myeloma
Adam Cohen et al. • 15 Apr 2023

Related Videos

Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals